Quick Facts

• Supports the management of advanced, hormone-dependent prostate cancer.
• Assists in the treatment of central precocious puberty (CPP) in children.
• Used within clinical protocols for specific forms of assisted reproductive technology (ART).

---

What Arvekap Treats: Main Uses and Benefits

Arvekap (triptorelin) is a prescription medication utilized in several distinct therapeutic domains, focusing on conditions that are influenced by specific natural hormones.

Therapeutic Domains

1. Prostate Cancer: Arvekap is indicated for the palliative management of advanced, hormone-dependent prostate cancer. It is used to help reduce the level of testosterone, which is a key factor in the growth of this type of cancer. This action helps to manage disease symptoms and support overall patient comfort.

2. Central Precocious Puberty (CPP): The medication is also utilized to address Central Precocious Puberty (CPP) in children who are two years of age and older. The objective of therapy is to manage the premature onset of puberty by modulating certain hormonal activity.

3. Assisted Reproductive Technology (ART): Arvekap may be incorporated into regimens for assisted reproductive technology to support controlled ovarian stimulation for specific procedures.

Arvekap is a component of a comprehensive care plan, administered under the direction of a qualified healthcare provider.

Regulatory References

1. NIH MedlinePlus guidance

Official Eligibility and Contraindications

Arvekap (triptorelin) use is strictly defined by regulatory documents, which establish absolute contraindications and specific population restrictions.

Classification	Population/Condition
Contraindicated	Individuals with known hypersensitivity to triptorelin, other GnRH agonists, or any component of the product.
Contraindicated	Females who are pregnant or who may become pregnant, and lactating (breastfeeding) females.

---

Age and Condition-Based Rules

Age-Related Eligibility: The medicine is generally approved for adult males with prostate cancer and for females in Assisted Reproductive Technology (ART) protocols. For Central Precocious Puberty (CPP), use is established only in children 2 years of age and older, with safety and efficacy not established in children under 2 years of age. Treatment for CPP is typically discontinued around the physiological age of puberty (e.g., bone age 12-14 years, depending on sex).

Restricted Use: Patients with known metastatic vertebral lesions or urinary tract obstruction require close observation upon initiation due to the risk of temporary symptom worsening. Caution is also advised, and monitoring is required, for patients with pre-existing cardiovascular risks (e.g., congenital long QT syndrome) or metabolic conditions such as diabetes or hyperglycemia. Official documents state that no specific dosage adjustment is generally required for renal or hepatic impairment.

The official interaction profile for Arvekap (Triptorelin) is primarily characterized by a low potential for pharmacokinetic drug interactions. Regulatory documentation confirms that Triptorelin is a peptide that is unlikely to be metabolized by major hepatic microsomal enzymes, such as the CYP450 system, nor is it expected to interact with the P-glycoprotein transporter. Triptorelin’s clearance is therefore defined as having minimal involvement from these common metabolic pathways.

The most significant documented concerns relate to pharmacodynamic interactions. Caution is advised with co-administration of medicinal products that are also known to prolong the QT interval, as Triptorelin may contribute to this additive risk. Caution is further required with drugs that affect the pituitary secretion of gonadotropins, which could potentially alter the intended hormonal suppression effect.

Population-specific data from regulatory studies indicates that Triptorelin systemic exposure (AUC) can increase significantly, up to two to four times, in patients with severe renal or severe hepatic impairment. Furthermore, due to the intramuscular injection route, caution is officially noted for patients concurrently treated with anticoagulants, owing to the potential risk of haematoma formation at the injection site. Formal interaction-related restrictions include a contraindication for individuals with known hypersensitivity to Triptorelin, its components, or other GnRH agonists.

Arvekap (triptorelin) is a synthetic agonist analogue of Gonadotropin-Releasing Hormone (GnRH). Its mechanism of action is centered on the anterior pituitary gland, where it initially binds to the GnRH receptors.

Modulating Pituitary GnRH Receptors

Initially, Triptorelin stimulates the GnRH receptors, leading to the transient release of the gonadotropins, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This initial release is followed by a critical molecular alteration.

Inducing Receptor Desensitization and Down-Regulation

Continuous exposure to the GnRH analogue induces sustained desensitization and down-regulation of the GnRH receptors on pituitary cells. This process subsequently reduces the pituitary's capacity for secretion, resulting in suppressed levels of LH and FSH.

Decreasing Peripheral Steroid Production

This sustained reduction in gonadotropin levels consequently diminishes their stimulatory effects on the gonads. This effect leads to a decreased peripheral production of sex steroids, specifically testosterone and estrogen, thereby modulating endocrine pathway activity.

How to Use Arvekap

Arvekap is administered exclusively as a long-acting, fixed-interval injection under the supervision of a qualified healthcare professional. The approved administration route is primarily by intramuscular (IM) injection into the gluteal area, though some regimens may permit a subcutaneous route. Due to its specific long-acting design, the choice of dose directly determines the fixed frequency of administration.

Standardized Dosing Regimens

The standard adult regimen for hormone-dependent prostate cancer is structured around three available depot strengths:

• A 3.75 mg dose is administered every 4 weeks.
• An 11.25 mg dose is administered every 12 weeks (3 months).
• A 22.5 mg dose is administered every 24 weeks (6 months).

These strengths are not interchangeable or additive for dosing purposes; the correct strength must be selected to match the required interval. Treatment for cancer indications is generally long-term, continuing on this fixed schedule.

Administration Conditions and Specific Populations

Proper use requires specific handling instructions for the powder and solvent preparation. The powder must be reconstituted only with the provided sterile water and the resulting suspension must be injected rapidly and without interruption immediately upon mixing to ensure the full dose is delivered. The injection site should be alternated periodically with each administration.

For the pediatric indication of Central Precocious Puberty (CPP), the labeled regimen is 22.5 mg administered every 24 weeks. No dosage adjustment is generally required for older adults or those with renal or hepatic impairment.

Research Evidence / Overview of Studies for Arvekap (Triptorelin)

---

Evidence for Use in Prostate Cancer Management

The use of Arvekap in advanced, hormone-dependent prostate cancer was studied in various clinical studies, including large Randomized Controlled Trials (RCTs) and long-term observational cohort analyses. These studies included adult men with locally advanced or metastatic prostate cancer. Researchers examined how the medicine affected specific outcomes related to systemic or functional imbalance, such as the achievement and tracking of very low testosterone levels (castrate levels), a relevant measurement in this type of therapy. Studies monitored changes in tumor markers, like Prostate-Specific Antigen (PSA), over defined time intervals. Research examined whether specific patterns of reduction in hormone levels were observed in the populations. Comparative evidence is lacking in the form of head-to-head RCTs against surgical castration for all long-term measures.

---

Evidence for Use in Central Precocious Puberty (CPP)

Studies examining Arvekap in Central Precocious Puberty (CPP) in children aged two years and older largely stems from open-label studies and single-arm Phase III trials, often followed by long-term observational follow-up. Research was evaluated in both boys and girls diagnosed with this condition. Key areas of research examined the suppression of specific hormones (LH, FSH, and sex hormones) to levels typically found before puberty. Additionally, researchers monitored physical development markers, such as the stabilization or reversal of secondary sex characteristics, and measurements related to skeletal maturation. Research exploring differences in final adult height compared to untreated individuals is limited by research methodology constraints.

---

Evidence for Use in Assisted Reproductive Technology (ART) Regimens

Arvekap was evaluated in studies related to Assisted Reproductive Technology (ART) protocols, with research primarily consisting of Randomized Controlled Trials (RCTs). These studies included adult women undergoing Controlled Ovarian Hyperstimulation (COH). The studies explored outcomes related to systemic or functional imbalance during the stimulation cycle, focusing on ovarian response and key endpoints of the ART process, including fertilization rates and the occurrence of clinical pregnancy. The protocols used for the medication may vary widely across trials, meaning that evidence quality varies across studies and the available evidence is insufficient to establish a universal optimal approach.

---

What is Still Uncertain about Arvekap's Evidence

For all indications, limited information is available regarding every possible long-term outcome axis, and subgroup findings for patients with pre-existing conditions remain uncertain. The research is ongoing to address some of these evidence gaps.

Key Studies & References

1. Triptorelin injection - MedlinePlus Drug Information
2. Systematic Review on GnRH agonists for the management of Central Precocious Puberty
3. Clinical Practice Guideline Summary for Hormone-Sensitive Prostate Cancer (e.g., NCCN/AUA)

Common questions about Arvekap (FAQ)

---

Q: Does it make you sleepy?

A: Official product information on Arvekap (tadalafil) indicates that dizziness is listed as an adverse reaction in clinical trials. While sleepiness is not typically reported as a common side effect, patients should be aware of the potential for dizziness, especially when performing tasks that require mental alertness.

Q: Is it safe long-term?

A: Regulatory studies for Arvekap (tadalafil) have examined its use over monitored clinical trial durations, which have included periods of up to 6 months to 1 year for chronic conditions like Erectile Dysfunction and Benign Prostatic Hyperplasia. Official product information summarizes the safety profile established during these monitored clinical trial durations.

Q: Can children 2 years old use it?

A: According to the regulatory labeling for Arvekap (tadalafil), the safety and effectiveness have not been established for individuals under 18 years of age. Therefore, Arvekap is not indicated for use in the pediatric population for Erectile Dysfunction or Benign Prostatic Hyperplasia.

Q: What is the recommended storage temperature?

A: Official product labeling specifies that Arvekap should be stored at room temperature, typically kept between 59 F and 86 F (15 C and 30 C). The medication should be stored in its original packaging and protected from excessive heat, moisture, and direct light.

Q: Can I drink alcohol while taking this medicine?

A: Both Arvekap (tadalafil) and alcohol are substances that can cause blood vessels to widen (vasodilation), which may lower blood pressure. Consuming large amounts of alcohol (e.g., 5 units or more) while taking this medicine may cause hypotension (low blood pressure), leading to symptoms like dizziness. Official information advises patients to be aware of this potential additive effect.

Q: What are the contraindications?

A: Official regulatory documents list situations where Arvekap is strictly contraindicated (must not be used). These include taking any form of organic nitrate (e.g., nitroglycerin) or taking a guanylate cyclase (GC) stimulator (e.g., riociguat). Additionally, Arvekap is contraindicated if there is a known serious hypersensitivity (allergic reaction) to tadalafil.

How to Store and Dispose of Arvekap?

Storage and disposal of Arvekap (triptorelin) must strictly follow official regulatory instructions to maintain product stability and safety.

Storage Requirements

The medicine must be stored in its original outer carton to protect it from light. The storage temperature must not exceed 25 C. For safety, keep the medicine out of the sight and reach of children.

Stability and Handling

Arvekap is a single-use product. The suspension, once prepared (reconstituted), must be used immediately as it is not stable for later use. Preparation must be done using an aseptic technique.

Disposal Instructions

Any unused medicine, expired product, and all associated materials must be disposed of according to local regulations. Used needles and syringes must be placed immediately into a dedicated, puncture-proof sharps container.